A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

Clinical trial NCT07579208 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07579208
Sponsor: M.D. Anderson Cancer Center
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Phase 1 NK Cell IL13Ra EGFRvIII Chimera Antigen Receptor (CAR)NR3C1 Recurrent Glioblastoma

Start date: 2026-10-24
Primary completion: 2028-07-30
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.